Work

Tumor immunologic heterogeneity influences response to radiation and combination immunotherapy

Year: 2015

Type: article

Abstract: Meeting abstracts Clinical trials of CTLA-4 and PD-1/PD-L1 antibodies (Ab) have shown responses limited to 10-30% of patients. Increasing evidence suggests radiation (RT) can enhance responses to checkpoint therapies. However, understanding of tumor-derived factors that influence response is

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p345

Authors: Todd Aguilera, Marjan Rafat, Mihalis Kariolis, Rie von Eyben, Edward Graves, Amato Giaccia

Institutions: Stanford Medicine, Stanford University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490